nanovaccine-based gene-immune therapy robustly elicits anti-tumor immune response in vivo
文献类型：会议论文
| 作者 | Lanlan Liu; Ce Wang; Yifan. Ma |
| 出版日期 | 2015 |
| 会议名称 | ChinaNANO2015 |
| 会议地点 | 中国北京国际会议中心 |
| 英文摘要 | Dendritic cell (DC)-based cancer vaccine immunotherapy is a promising method, but so far has demonstrated limited clinical benefits. Tumor associated dendritic cells (TADCs) are less matured with poor responsiveness to Toll-like receptor (TLR) stimulation, which represent a major obstacle for developing effective vaccine. Therefore, it is highly desirable to overcome TADC dysfunction in cancer patients in order to improve the therapeutic efficacy of cancer vaccines. In the present study, Poly I: C (PIC, a TLR3 agonist), miR-148a inhibitor and OVA antigen were co-encapsulated by poly (ethylene glycol)-b-poly (L-lysine)-b-poly (L-leucine) (PEG-PLL-PLLeu) polypeptide micelles to generate PMP/OVA/148ai nanovaccine, which was aimed to effectively overcome DC dysfunction in vivo by deleting miR-148a expression. The results showed that TADCs dysfunction has been related with miR-148a hyperactivity. Inhibition of miR-148a augmented the responsiveness of TADC to TLR3 stimulates. Furthermore, PMP/OVA/148ai effectively decreased miR-148a expression in TADCs and simultaneously facilitated TADC maturation and activation both in vitro and in vivo. Moreover, the immunization of PMP/OVA/148ai rather than PMP/OVA effectively decreased immunosuppressive cells in the spleen and tumor-draining lymph nodes, which thereby led to potent antitumor immune responses and dramatic tumor regression with prolonged survival. Hence, in vivo co-delivery of immunopotentiator (PIC) and immunosuppressive miRNA inhibitor (miR-148a inhibitor) by nanovaccines are expected to be a promising strategy to enhance the anti-tumor efficacy of therapeutic vaccines by modulating TADCs and overcoming tumor immunosuppression. |
| 收录类别 | 其他 |
| 语种 | 英语 |
| 源URL | [http://ir.siat.ac.cn:8080/handle/172644/7426]  |
| 专题 | 深圳先进技术研究院_医药所 |
| 作者单位 | 2015 |
| 推荐引用方式 GB/T 7714 | Lanlan Liu,Ce Wang,Yifan. Ma. nanovaccine-based gene-immune therapy robustly elicits anti-tumor immune response in vivo[C]. 见:ChinaNANO2015. 中国北京国际会议中心. |
入库方式： OAI收割
来源：深圳先进技术研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。